There are a number of interesting cancer drugs in development that may receive approval this year.  Many of them are from biotech rather than pharma and focused on niche indications. First up is Genzyme's Clolar (clofarabine), which was filed as a supplemental application in the US on November 24th...

Biotech, cancer, deals Luke Timmerman wrote: The recession will surely kill off some biotech companies that lack hard cash and the hard data that shows their experimental drugs can improve patients’ lives. But after I heard Seattle Genetics CEO Clay Siegall tell the story of how his company ra...

There was a problem finding somewhere to park... Then finding the correct change for a can of Pepsi from one of the dispensing machines... The thumb prick went OK - no fears - no tears - a veteran now... All the play stations were occupied - we hate to wait... It was a very busy clinic... Nothing le...